Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 13/20 | 0.61 |
| ▸ | ELANE | P08246 | 1/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 3/20 | 0.50 |
| ▸ | REN | P00797 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2162326 | 1.00 | CMA1 (0.61) | CMA1ELANECTSLCTSBCTSK | |
| SCHEMBL6284248 | 1.00 | CMA1 (0.61) | CMA1ELANECTSLCTSBCTSK | |
| SCHEMBL8168155 | 1.00 | CMA1 (0.61) | CMA1ELANECTSLCTSBCTSK | |
| SCHEMBL17378396 | 1.00 | CMA1 (0.61) | CMA1ELANECTSLCTSBCTSK | |
| SCHEMBL6740347 | 0.92 | CMA1 (0.53) | CMA1ELANECTSLCTSBCTSK | |
| SCHEMBL29787416 | 0.91 | CMA1 (0.53) | CMA1ELANECTSLCTSBCTSK | |
| SCHEMBL13258959 | 0.90 | CMA1 (0.51) | CMA1ELANECTSLCTSBCTSK | |
| SCHEMBL28603270 | 0.89 | CMA1 (0.51) | CMA1ELANEACEREN | |
| SCHEMBL28603273 | 0.89 | CMA1 (0.51) | CMA1ELANEACEREN | |
| SCHEMBL28603275 | 0.89 | CMA1 (0.51) | CMA1ELANEACEREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156509-A1 | Tri-peptide Inhibitors of Serine Elastases | ACCUTHERA, INC. (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156509-A1 | Tri-peptide Inhibitors of Serine Elastases | SCTR, CTRC, SERPINB1 | CMA1 18/4885ELANE 4/4885CTSL 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.